Categories: NewsPharmaceutical

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Staff

Recent Posts

DIGITAL HEALTH LEADER JMIR PUBLICATIONS ANNOUNCES ITS 2025 IMPACT FACTOR RESULTS

The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with…

4 hours ago

Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption

PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today…

4 hours ago

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of…

4 hours ago

AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025…

4 hours ago